Wang Ying, Liu Ping, Xu Yan, Zhang Weihao, Tong Lina, Guo Zhi, Ni Hong
Department of Interventional Therapy, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, People's Republic of China.
Cancer Chemother Pharmacol. 2015 Feb;75(2):255-62. doi: 10.1007/s00280-014-2622-6. Epub 2014 Nov 27.
To investigate the role of preoperative neutrophil-to-lymphocyte ratio (NLR) in prediction of response to first-line platinum-based chemotherapy and survival outcome in serous ovarian cancer (SOC) patients.
Clinicopathologic data were reviewed for patients with SOC treated with primary cytoreduction followed by platinum-based chemotherapy. The correlations of NLR value with clinicopathological features, clinical response to chemotherapy, and survival outcome were further explored.
High preoperative NLR was significantly associated with advanced FIGO stage, histological grade, increased serum CA-125 level, and positive lymph node metastasis (P < 0.05, respectively). SOC patients in the third and fourth NLR quartile had significantly lower complete response rates compared to those in the first NLR quartile. In addition, survival analysis identified NLR as an independent prognostic factor for both PFS (HR 2.262, 95% CI 1.342-3.811; P = 0.002) and OS (HR 3.254, 95% CI 1.741-6.084; P < 0.001) in SOC patients.
Our findings indicated that high levels of preoperative NLR might be a potential biomarker of worse response to first-line platinum-based chemotherapy and poor clinical outcomes in patients with SOC. Further validation of this easily available parameter as a potential stratification tool in prospective studies should be encouraged.
探讨术前中性粒细胞与淋巴细胞比值(NLR)在预测浆液性卵巢癌(SOC)患者一线铂类化疗反应及生存结局中的作用。
回顾接受初次肿瘤细胞减灭术及铂类化疗的SOC患者的临床病理资料。进一步探讨NLR值与临床病理特征、化疗临床反应及生存结局的相关性。
术前高NLR与国际妇产科联盟(FIGO)晚期分期、组织学分级、血清CA-125水平升高及淋巴结转移阳性显著相关(P均<0.05)。与第一NLR四分位数组的SOC患者相比,第三和第四NLR四分位数组的患者完全缓解率显著更低。此外,生存分析确定NLR是SOC患者无进展生存期(HR 2.262,95%CI 1.342 - 3.811;P = 0.002)和总生存期(HR 3.254,95%CI 1.741 - 6.084;P < 0.001)的独立预后因素。
我们的研究结果表明,术前高NLR水平可能是SOC患者对一线铂类化疗反应较差及临床结局不佳的潜在生物标志物。应鼓励在前瞻性研究中进一步验证这一易于获得的参数作为潜在分层工具的有效性。